Table Graph
      published meta-analysis   sensitivity analysis   studies

tocilizumab in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsMARIPOSA, 2021 (REV) 0.70 [0.21; 2.37] 0.70[0.21; 2.37]MARIPOSA, 2021 (REV)10%97NAnot evaluable hospital dischargedetailed resultsMARIPOSA, 2021 (REV) 1.14 [0.72; 1.82] 1.14[0.72; 1.82]MARIPOSA, 2021 (REV)10%NAnot evaluable mechanical ventilationdetailed resultsMARIPOSA, 2021 (REV) 1.14 [0.48; 2.71] 1.14[0.48; 2.71]MARIPOSA, 2021 (REV)10%97NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-27 16:23 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 395 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons